SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

New River Pharmaceuticals Inc – ‘8-K’ for 6/26/06

On:  Monday, 6/26/06, at 2:34pm ET   ·   For:  6/26/06   ·   Accession #:  1140361-6-9539   ·   File #:  0-50851

Previous ‘8-K’:  ‘8-K’ on / for 6/20/06   ·   Next:  ‘8-K’ on / for 6/30/06   ·   Latest:  ‘8-K’ on 4/24/07 for 4/18/07

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/26/06  New River Pharmaceuticals Inc     8-K:8,9     6/26/06    2:1.1M                                   Summit Fin’l Printing

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         New River Pharmaceutical 8-K 6-26-2006              HTML     22K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    177K 


8-K   —   New River Pharmaceutical 8-K 6-26-2006


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  New River Pharmaceutical 8-K 6-26-2006  


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)


NEW RIVER PHARMACEUTICALS INC.
(Exact name of Registrant as specified in charter)


Virginia
54-1816479
(State or other jurisdiction of incorporation)
(Commission file number)
(IRS employer identification no.)


1881 Grove Avenue, Radford, Virginia  
24141
(Address of principal executive offices)
(Zip code)

Registrant’s telephone number, including area code
(540) 633-7978
 
Not applicable
(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 




Section 8 — Other Events

Item 8.01. Other Events.

On June 26, 2006, Dr. Donald Jasinski, Professor of Medicine, Chief Center for Chemical Dependence, Johns Hopkins Bayview Medical Center, the principal investigator with respect to the A01, A02 and A03 clinical abuse liability studies on NRP104, provided greater detail about the studies and their results during a conference call. NRP104 is the subject of a new drug application filed by New River Pharmaceuticals Inc. with the U.S. Food and Drug Administration on December 6, 2005, seeking approval for three therapeutic doses (30, 50 and 70 mg) of NRP104 for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in pediatric populations. Dr. Jasinski’s presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference.
 

 
Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

 
(c)
Exhibits.

 
99.1
Presentation made on June 26, 2006 by Dr. Donald Jasinski regarding clinical abuse liability studies.
 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: June 26, 2006

   
NEW RIVER PHARMACEUTICALS INC.
 
         
         
   
By:
/s/ Randal J. Kirk
 
     
Randal J. Kirk
 
     
Chief Executive Officer and President
 


 
EXHIBIT INDEX

Exhibit Number
 
Exhibit
     
 
Presentation made on June 26, 2006 by Dr. Donald Jasinski regarding clinical abuse liability studies.
 
 


Dates Referenced Herein

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period End:6/26/06None on these Dates
12/6/05
 List all Filings 
Top
Filing Submission 0001140361-06-009539   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 9:10:17.1am ET